Hasil Pencarian (12560)
Halaman 39 / 252Deskripsi belum tersedia.
Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor ef…
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels. ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investiga…
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553]. A phase I study (NCT04522089) will investigate the safety and immunogenicity of t…
Adinazolam (Deracyn®) is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was first developed to enhance the antidepressant effects of [alprazolam]. It has never been approved by the FDA for clin…
Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem …
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cros…
ADL-5859 is under investigation in clinical trial NCT00626275 (Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis).
ADL5859 is a novel, oral compound that targets the Delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain.
Adlinacogene civaparvovec is an investigational _in vivo_ genome editing therapeutic product. It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX…
Adomeglivant has been investigated for the basic science of Type 2 Diabetes.
JNJ-38431055 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regre…
Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).
Adrafinil is a mild central nervous system stimulating drug typically employed to relieve excessive sleepiness and inattention in geriatric patients. It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil d…
Deskripsi belum tersedia.
Adrenomedullin is under investigation in clinical trial NCT06072118 (Adrenomedullin for CADASIL).
Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).
ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. ADU-S100 (MIW815) activates all known human and mouse STINGs, and e…
Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-? plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab].[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow…
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD,…
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in ma…
AEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]
AEM-28-14 is an analog of [AEM-28], an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering efficacy and a several-fold increase in drug tolerability.[L45909] It is being investigated for lipid disorders such as homozygous familia…
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.